Eli Lilly and Company - Begin Period Cashflow

Eli Lilly and Company's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Begin-Period-Cashflow" stands at 13.11 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value since 09/30/2022.

Eli Lilly and Company's third quarter result of 3.38 Billion USD for the item "Begin Period Cashflow" represents an increase of 9.14 percent compared to it's second quarter result.

Also, Eli Lilly and Company's third quarter result of 3.38 Billion USD for the item "Begin Period Cashflow" represents an increase of 4.72 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), Eli Lilly and Company's third quarter result of 13.11 Billion USD for the item "Begin Period Cashflow" represents an increase of 1.18 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 20.43 percent compared to the value the year prior.
The 1 year change in percent is 20.43.
The 3 year change in percent is 3.29.
The 5 year change in percent is 64.54.
The 10 year change in percent is -2.32.

The Serie's long term average value is 14.89 Billion United States Dollars. It's latest available value, on 09/30/2025, is 11.98 percent lower, compared to it's long term average value.
The Serie's change in percent from it's minimum value, on 06/30/2020, to it's latest available value, on 09/30/2025, is +66.11%.
The Serie's change in percent from it's maximum value, on 03/31/2019, to it's latest available value, on 09/30/2025, is -51.20%.